Suc-APA-pNA peptide [Suc-Ala-Pro-Ala-pNA; MW: 477.5] |
SP-51205-1 |
Alpha Diagnostics |
1 mg |
EUR 169.2 |
Igg Antibody Laboratories manufactures the igg increased from from112 to 477.5 reagents distributed by Genprice. The Igg Increased From From112 To 477.5 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact igg antibody. Other Igg products are available in stock. Specificity: Igg Category: Increased Group: From From112
JBS True Blue |
MiTeGen |
300 µl |
EUR 16 |
Description: JBS True Blue |
Suc-APA-pNA peptide [Suc-Ala-Pro-Ala-pNA; MW: 477.5] |
Alpha Diagnostics |
1 mg |
EUR 169.2 |
Goat True insulin ELISA kit |
BlueGene |
96T |
EUR 700 |
Description: ELISA |
From From112 information
PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 750) |
MBS6335233-01mL |
MyBiosource |
0.1mL |
EUR 980 |
PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 750) |
MBS6335233-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
PMS2 (Postmeiotic Segregation Increased 2) |
MO47015 |
Neuromics |
100 ul |
EUR 418.8 |
PMS2 (Postmeiotic Segregation Increased 2) |
MBS556114-01mL |
MyBiosource |
0.1mL |
EUR 455 |
PMS2 (Postmeiotic Segregation Increased 2) |
MBS556114-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1895 |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5202-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5202-20UG |
NSJ Bioreagents |
20ug |
EUR 160.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5202SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5203-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5203-20UG |
NSJ Bioreagents |
20ug |
EUR 160.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5203SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
7th Canister (increased storage capacity) 11 in (VHC35) |
TW-R036-9C27 |
MiTeGen |
11 in |
EUR 86 |
Description: 7th Canister (increased storage capacity) 11 in (VHC35) |
Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Antibody |
N1752-100uL |
Assay Biotech |
100uL |
EUR 122.5 |
Description: Human Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Mouse Monoclonal Antibody |
Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Antibody |
N1752-50uL |
Assay Biotech |
50uL |
EUR 66.5 |
Description: Human Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Mouse Monoclonal Antibody |
Streptokinase from from Streptococcus sp., Recombinant |
NATE-1630 |
Creative Enzymes |
10ku |
EUR 324 |
Rabbit Anti-Bovine IgG (whole IgG from colostrum), unlabeled |
80516 |
Alpha Diagnostics |
1 ml |
EUR 242.4 |